Clinical Trials on Complement Deficiency

Total 9040 results

CSL Behring

Recruiting

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Complement Deficiencies

Australia
Catalyst Biosciences

Terminated

Screening Study to Identify Patients With Complement Factor I Deficiencies

Previous Diagnosis With a Complement-mediated Disease and/or With Clinical Manifestations Reasonably Associated With Complement Factor I Deficiency

United States
First Affiliated Hospital, Sun Yat-Sen University

Completed

The Predictive Value of Complement C3 in Patients With Advanced Gastric Cancer

Gastric Cancer | Surgery | Complement Component Deficiency

China
Institut Pasteur de Lille

Completed

Fish Collagen Peptide Food Supplement on Weight and Body Composition (NATICOL)

Weight Management | Food Complement

France
University Hospital, Montpellier

Terminated

The Role of the Coagulation Pathways in Recurrent Angioedema (Angiocoag)

Chronic Spotaneous Urticaria, Idiopathic Non Histaminergic Angioderma, Hereditary Angioedema With C1 Inhibitor Deficiency

France
Hospital Universitari Vall d'Hebron Research Institute
Hospital Universitario La Paz

Not yet recruiting

Identification and Characterization of Genetic Variants in Hereditary Angioedema (GENOMAEH_01)

Hereditary Angioedema With C1 Esterase Inhibitor Deficiency

Spain
Heeger, Peter, M.D.
Icahn School of Medicine at Mount Sinai; Alexion Pharmaceuticals

Terminated

Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation

Kidney Transplantation | Delayed Graft Function | Complement Activity

United States
KalVista Pharmaceuticals, Ltd.

Recruiting

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Hereditary Angioedema

United States, Bulgaria, France, Greece, Israel, Netherlands, Spain, United Kingdom, Australia, Germany, South Africa, Slovakia, Austria, New Zealand, Romania, Canada, Japan
KalVista Pharmaceuticals, Ltd.

Recruiting

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Hereditary Angioedema

United States, Bulgaria, France, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, North Macedonia, Poland, Spain, United Kingdom, Australia, Germany, South Africa, Austria, Portugal, Slovakia, Romania, Canada, Saudi Arabia, Japa...
Pharming Technologies B.V.
US Hereditary Angioedema Association

Completed

Patient Registry to Evaluate the Real-world Safety of Ruconest®

Hereditary Angioedema

United States
BioCryst Pharmaceuticals

Active, not recruiting

Berotralstat Treatment in Children With Hereditary Angioedema (APeX-P)

Hereditary Angioedema | Pediatric

Spain, Austria, Canada, France, Germany, Israel, Italy, Poland, Romania, United Kingdom
Ionis Pharmaceuticals, Inc.

Active, not recruiting

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

Hereditary Angioedema

Netherlands, United States
KalVista Pharmaceuticals, Ltd.

Completed

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Hereditary Angioedema

United States, Australia, Bulgaria, Canada, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, North Macedonia, Poland, Portugal, Puerto Rico, Romania, Slovakia, Spain, United Kingdom
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Angioedema

United States, Spain, Netherlands, Hungary, Italy, Canada, Germany, France, Japan, Poland
Takeda

Completed

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

Angioedemas, Hereditary

Argentina
BioCryst Pharmaceuticals

Completed

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE (APeX-2)

Hereditary Angioedema | HAE

United States, Austria, Canada, Czechia, France, Germany, Hungary, North Macedonia, Romania, Spain, United Kingdom
Shire

Completed

A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

Hereditary Angioedema

United States
Shire
Jerini AG

Completed

EASSI - Evaluation of the Safety of Self-Administration With Icatibant (EASSI)

Hereditary Angioedema

Spain, Argentina, Austria, Denmark, France, Germany, Israel, Italy, Switzerland, United Kingdom
BioCryst Pharmaceuticals

Completed

A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions

Hereditary Angioedema

United Kingdom
Assistance Publique - Hôpitaux de Paris

Completed

A Call Center During HAE Attacks (SOS HAE) (SOS AOH)

Hereditary Angioedema

France
BioCryst Pharmaceuticals

Completed

12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks (OPuS-2)

Hereditary Angioedema | HAE

France, United Kingdom, Germany, United States, Belgium, Hungary, Italy, Canada
Johann Wolfgang Goethe University Hospital
CSL Behring; University of Milan; PharmaPart; Clinical trial center Rhine-Main; ZKI... and other collaborators

Completed

Berinert P Study of Subcutaneous Versus Intravenous Administration (PASSION)

Hereditary Angioedema

Germany
University Hospital, Lille
CSL Behring; Laboratoire français de Fractionnement et de Biotechnologies; Oc... and other collaborators

Terminated

Systematic Search for Primary Immunodeficiency in Adults With Infections (SPIDAC)

Pneumococcal Infections | Pneumonia, Bacterial | Meningitis, Bacterial | Otitis Media | Chronic Sinus Infection | Streptococcal Infection | Antibody Deficiency | Complement Deficiency | Neisseria Infections | Haemophilus Influenza

France
Astria Therapeutics, Inc.

Recruiting

A Study of STAR-0215 in Participants With Hereditary Angioedema

Hereditary Angioedema

United States, United Kingdom, Canada, Germany, Bulgaria
ADARx Pharmaceuticals, Inc.

Recruiting

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Hereditary Angioedema

Australia
Pharming Technologies B.V.

Recruiting

C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

Hereditary Angioedema

Germany, Bulgaria, Croatia, Czechia, France, Hungary, Italy, North Macedonia, Poland, Slovakia, Norway, Slovenia, Sweden
CSL Behring

Active, not recruiting

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Hereditary Angioedema

Australia, Canada, United States, New Zealand, Germany, Hong Kong, Netherlands, Taiwan, Czechia, Israel, Hungary, Japan, Russian Federation, Spain
Intellia Therapeutics

Active, not recruiting

NTLA-2002 in Adults With Hereditary Angioedema (HAE) (NTLA-2002)

Hereditary Angioedema

France, New Zealand, Germany, United Kingdom, Netherlands, Australia
Astria Therapeutics, Inc.

Enrolling by invitation

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

Hereditary Angioedema

United States
BioCryst Pharmaceuticals

Active, not recruiting

Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies (APeX-A)

Hereditary Angioedema | HAE

France, North Macedonia, Poland, Korea, Republic of, Slovakia, South Africa, Czechia
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema

Hereditary Angioedema

United States, Netherlands
KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom
Shire
Halozyme Therapeutics

Completed

A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase

Hereditary Angioedema

United States
Shire

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration

Hereditary Angioedema

United States
Shire

Completed

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

Angioedema

United States
Shire

Completed

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks (CHANGE 2)

Hereditary Angioedema

United States
Shire

Completed

Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects

Hereditary Angioedema

United States
KalVista Pharmaceuticals, Ltd.

Completed

A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
BioCryst Pharmaceuticals

Completed

A Relative Bioavailability Study of Two Formulations of BCX7353

Hereditary Angioedema

United Kingdom
Pharming Technologies B.V.

Completed

A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

Hereditary Angioedema

United States, Canada, Czechia, Italy, Macedonia, The Former Yugoslav Republic of, Romania, Serbia
BioCryst Pharmaceuticals

Completed

An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates

Hereditary Angioedema

United Kingdom
Massachusetts General Hospital
Shire Human Genetic Therapies, Inc.

Completed

Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE (IHA)

Hereditary Angioedema

United States
BioCryst Pharmaceuticals

Completed

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers

Hereditary Angioedema

United Kingdom
Pharming Technologies B.V.

Completed

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

Hereditary Angioedema

United States, Bulgaria, Canada, Hungary, Israel, Italy, Macedonia, The Former Yugoslav Republic of, Poland, Romania, Serbia, South Africa
CSL Behring

Completed

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

Hereditary Angioedema

United States, Canada
CSL Behring

Completed

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

Hereditary Angioedema

Bulgaria, United States, Poland, Spain, Hungary, United Kingdom, Russian Federation, Macedonia, The Former Yugoslav Republic of, Argentina, Australia, Canada, Czech Republic, Israel, Romania, Sweden
BioCryst Pharmaceuticals

Completed

Study to Determine How BCX4161 is Metabolized and Eliminated by the Body

Hereditary Angioedema

United Kingdom
Intellia Therapeutics

Not yet recruiting

Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002

Hereditary Angioedema

France, New Zealand, United Kingdom
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

Hereditary Angioedema

United States, Puerto Rico, Belgium, Bulgaria, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Spain, Turkey, United Kingdom
BioMarin Pharmaceutical

Recruiting

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema (HAErmony-1)

Hereditary Angioedema | HAE

United States, Spain, Australia

Clinical Trials on Complement Deficiency

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations